Epratuzumab (LymphoCide)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 17:45, 5 August 2019 by Jwarner (talk | contribs) (Jwarner moved page Epratuzumab (humanised anti-CD22 antibody) to Epratuzumab (LymphoCide): brand name available)
Jump to navigation Jump to search

Mechanism of action

Anti-CD22 antibody

Preliminary data

Acute lymphocytic leukemia

  1. Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M, Appelbaum FR. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol. 2014 May;165(4):504-9. Epub 2014 Mar 3. PubMed link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Epratuzumab_(LymphoCide)&oldid=39351"